Delaware |
001-35312
|
No. 68-0533453
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number) | (I.R.S. Employer Identification No.) |
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
NUWE | Nasdaq Capital Market |
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) |
Exhibits
|
Exhibit No. |
Description |
99.1 |
Press Release, dated August 10, 2021, reporting the financial results of Nuwellis, Inc. for the three and six months ended June 30, 2021.
|
Date: August 10, 2021
|
NUWELLIS, INC.
|
||
By:
|
/S/ Nestor Jaramillo
|
||
Name:
|
Nestor Jaramillo
|
||
Title:
|
President and Chief Executive Officer
|
• |
Reported record quarterly revenue of $2.5 million, a 35 percent increase compared to the prior year period
|
• |
Realized strong sequential growth across all customer markets and recorded the sixth consecutive quarter with double-digit revenue growth vs. prior year
|
• |
Welcomed George Montague, former CFO and COO of Smiths Medical, as new CFO
|
• |
Welcomed Neil Ayotte, a 16-year veteran of Medtronic plc and most recently EVP & General Counsel of Bluestem Group, as Senior VP, General Counsel, Secretary and Chief Compliance Officer
|
• |
Received Category III CPT code for the use of therapeutic ultrafiltration, effective January 1, 2022
|
• |
Announced a three-year national purchase agreement with Premier, Inc., one of the nation’s largest group purchasing organizations
|
• |
Ended the quarter with $24.0 million in cash and no debt
|
• |
Critical Care continued its strong momentum, driven by increased utilization and unit placements at hospitals in the ICU setting across the country. With COVID-related hospitalizations in the U.S.
having significantly declined since the vaccine rollout, increased utilization among non-COVID critically ill patients remains a durable growth trend.
|
• |
Pediatric revenue delivered strong double-digit sequential revenue growth for the second straight quarter primarily due to increased penetration and utilization at established accounts, in addition to
console sales to new customers.
|
• |
Heart Failure revenue increased sequentially due to more normalized patient behavior and increased access to hospitals as COVID-19 infection rates decline.
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Net sales
|
$
|
2,508
|
$
|
1,863
|
$
|
4,426
|
$
|
3,493
|
||||||||
Cost of goods sold
|
997
|
664
|
1,949
|
1,460
|
||||||||||||
Gross profit
|
1,511
|
1,199
|
2,477
|
2,033
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Selling, general and administrative
|
5,063
|
4,234
|
10,300
|
8,770
|
||||||||||||
Research and development
|
1,174
|
885
|
2,121
|
1,749
|
||||||||||||
Total operating expenses
|
6,237
|
5,119
|
12,421
|
10,519
|
||||||||||||
Loss from operations
|
(4,726
|
)
|
(3,920
|
)
|
(9,944
|
)
|
(8,486
|
)
|
||||||||
Other income (expense), net
|
(2
|
)
|
—
|
(3
|
)
|
—
|
||||||||||
Loss before income taxes
|
(4,728
|
)
|
(3,920
|
)
|
(9,947
|
)
|
(8,486
|
)
|
||||||||
Income tax expense
|
(3
|
)
|
(2
|
)
|
(5
|
)
|
(4
|
)
|
||||||||
Net loss
|
$
|
(4,731
|
)
|
$
|
(3,922
|
)
|
$
|
(9,952
|
)
|
$
|
(8,490
|
)
|
||||
Basic and diluted loss per share
|
$
|
(0.72
|
)
|
$
|
(3.10
|
)
|
$
|
(2.04
|
)
|
$
|
(11.31
|
)
|
||||
Weighted average shares outstanding – basic and diluted
|
6,532
|
1,264
|
4,887
|
906
|
||||||||||||
Other comprehensive loss:
|
||||||||||||||||
Foreign currency translation adjustments
|
$
|
—
|
$
|
(2
|
)
|
$
|
(3
|
)
|
$
|
(5
|
)
|
|||||
Total comprehensive loss
|
$
|
(4,731
|
)
|
$
|
(3,924
|
)
|
$
|
(9,955
|
)
|
$
|
(8,495
|
)
|
June 30,
2021
|
December 31, 2020
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$
|
23,978
|
$
|
14,437
|
||||
Accounts receivable
|
1,177
|
905
|
||||||
Inventories
|
2,656
|
2,957
|
||||||
Other current assets
|
413
|
237
|
||||||
Total current assets
|
28,224
|
18,536
|
||||||
Property, plant and equipment, net
|
1,260
|
1,200
|
||||||
Operating lease right-of-use asset
|
156
|
255
|
||||||
Other assets
|
—
|
21
|
||||||
TOTAL ASSETS
|
$
|
29,640
|
$
|
20,012
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Accounts payable
|
$
|
1,787
|
$
|
1,097
|
||||
Accrued compensation
|
1,577
|
2,192
|
||||||
Current portion of operating lease liability
|
160
|
206
|
||||||
Current portion of finance lease liability
|
25
|
24
|
||||||
Other current liabilities
|
54
|
66
|
||||||
Total current liabilities
|
3,603
|
3,585
|
||||||
Operating lease liability
|
—
|
55
|
||||||
Finance lease liability
|
41
|
54
|
||||||
Total liabilities
|
3,644
|
3,694
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity
|
||||||||
Series A junior participating preferred stock as of June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, none outstanding
|
—
|
—
|
||||||
Series F convertible preferred stock as of both June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares
|
—
|
—
|
||||||
Preferred stock as of both June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding
|
—
|
—
|
||||||
Common stock as of June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 6,532,018 and 2,736,060,
respectively
|
—
|
—
|
||||||
Additional paid‑in capital
|
269,296
|
249,663
|
||||||
Accumulated other comprehensive loss:
|
||||||||
Foreign currency translation adjustment
|
(10
|
)
|
(7
|
)
|
||||
Accumulated deficit
|
(243,290
|
)
|
(233,338
|
)
|
||||
Total stockholders’ equity
|
25,996
|
16,318
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
29,640
|
$
|
20,012
|
Six months ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Operating Activities:
|
||||||||
Net loss
|
$
|
(9,952
|
)
|
$
|
(8,490
|
)
|
||
Adjustments to reconcile net loss to cash flows used in operating activities:
|
||||||||
Depreciation and amortization
|
256
|
151
|
||||||
Stock-based compensation expense, net
|
736
|
727
|
||||||
Loss on disposal of property and equipment
|
—
|
46
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(272
|
)
|
(179
|
)
|
||||
Inventory
|
122
|
(1,104
|
)
|
|||||
Other current assets
|
(176
|
)
|
20
|
|||||
Other assets and liabilities
|
9
|
112
|
||||||
Accounts payable and accrued expenses
|
75
|
(43
|
)
|
|||||
Net cash used in operating activities
|
(9,202
|
)
|
(8,760
|
)
|
||||
Investing Activities:
|
||||||||
Purchases of property and equipment
|
(137
|
)
|
(69
|
)
|
||||
Net cash used in investing activities
|
(137
|
)
|
(69
|
)
|
||||
Financing Activities:
|
||||||||
Proceeds from public stock offerings, net
|
18,896
|
13,040
|
||||||
Proceeds from warrant exercises
|
1
|
2,340
|
||||||
Payments on finance lease liability
|
(14
|
)
|
(4
|
)
|
||||
Net cash provided by financing activities
|
18,883
|
15,376
|
||||||
Effect of exchange rate changes on cash
|
(3
|
)
|
(5
|
)
|
||||
Net increase in cash and cash equivalents
|
9,541
|
6,542
|
||||||
Cash and cash equivalents - beginning of period
|
14,437
|
1,279
|
||||||
Cash and cash equivalents - end of period
|
$
|
23,978
|
$
|
7,821
|
||||
Supplemental cash flow information
|
||||||||
Inventory transferred to property, plant and equipment
|
$
|
179
|
$
|
112
|
||||
Equipment acquired through finance lease liability
|
$
|
—
|
$
|
67
|